218 results on '"Schenkein, David P."'
Search Results
2. Supplementary Table 1 from Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
3. Supplementary Table 3 from Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
4. Supplementary Table 2 from Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
5. Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
6. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
7. Phase I Trials : Bortezomib Alone and in Combination With Standard Chemotherapies
8. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
9. Therapy of diffuse aggressive lymphomas
10. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
11. The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study
12. Antibody-based therapeutics: Focus on prostate cancer
13. A phase 2 study of bortezomib in relapsed, refractory myeloma
14. Phase I Trials
15. Use of Proteasome Inhibition in the Treatment of Lung Cancer
16. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
17. Preclinical Data with Bortezomib in Lung Cancer
18. Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission
19. A 65-year-old man with mediastinal Hodgkin's disease and a pelvic mass
20. Bortezomib in Multiple Myeloma
21. Pancytopenia, splenomegaly, and retinal hemorrhage in a 52-year-old diabetic man
22. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation
23. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma
24. Neoplasms and Transplantation -- Trading Swords for Plowshares
25. Recommended Guidelines for the Management of Autologous and Allogeneic Bone Marrow Transplantation: A Report from the Eastern Cooperative Oncology Group (ECOG)
26. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation
27. Hematology.
28. Intravenous IgG for treatment of autoimmune disease
29. Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor
30. Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome
31. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation
32. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
33. Therapy of diffuse aggressive lymphomas
34. Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition
35. Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate
36. Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
37. IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model
38. AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model
39. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
40. Reevaluating the Accelerated Approval Process for Oncology Drugs
41. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells
42. Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes
43. Prospective evaluation of serial 2-hydroxyglutarate in acute myeloid leukemia (AML) to determine response to therapy and predict relapse.
44. Cancer-Associated Isocitrate Dehydrogenase Mutations
45. Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
46. 2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels
47. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
48. Borrelia burgdorferi in Joint Fluid in Chronic Lyme Arthritis
49. Accelerated Bone Formation Causing Profound Hypocalcemia in Acute Leukemia
50. Abstract 5452: Cancer-associated metabolite 2-hydroxyglutarate accumulates in AML with IDH1/2 mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.